Pharmaceutical analyst Dr Martin Hall presents his initiated research on ImmuPharma PLC (AIM:IMM, OTC:IMMPF) ahead of next month’s FDA response which, the analyst, expects will trigger the start of Phase 3 for the company’s lead drug, called Lupuzor.
Hall, who penned his research for UK-based broker Stanford Capital, describes it as “an interesting time” for ImmuPharma, following a restructuring which leaves the company positioned with two late-stage clinical indications, and two pre-clinical-stage anti-infectives.
The analyst highlighted that over the past two years, ImmuPharma’s development and commercial partner, Avion, has played an instrumental role in liaising with the FDA regarding a pivotal clinical trial with Lupuzor for the treatment of lupus.